Navigation Links
Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
Date:7/29/2008

y and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward- looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable la
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
2. ThreeWire Expands Presence in the Pharmaceutical Arena
3. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
4. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
7. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
8. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
9. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
10. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
11. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015  scPharmaceuticals, ... transformative pharmaceutical products for subcutaneous delivery, announced ... trial of its investigational proprietary drug product, ... edema associated with congestive heart failure. ... is developing a proprietary patch pump.  The ...
(Date:4/21/2015)... 2015 Progyny, Inc., the new combined ... that it has secured additional capital from investors including ... One and Merck Serono Ventures. The funding will enable ... best fertility outcomes by aligning science, technology, clinics and ... for families seeking fertility solutions and we are committed ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 YourEncore, ... the life sciences, consumer products and food sciences ... and the Alliance for Clinical Research Excellence and ... system for conducting clinical research, have partnered to ... , YourEncore brings to ACRES experts ...
(Date:4/20/2015)... , April 20, 2015 Orthobiologics ... healing bone injuries. The orthobiologics market is a rewarding ... its stakeholders. The global orthobiologics market report defines and ... revenue. The global orthobiologics market was valued at $5,712.4 ... million by 2019, at a CAGR of 6.7% from ...
Breaking Biology Technology:scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 3Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 3Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3
... technique long used by statisticians to analyze data is ... learning, Alzheimer,s and Parkinson,s diseases and stroke. Researchers ... Science Center at Houston (UTHealth) reported today in the ... fluorescence resonance energy transfer (FRET) techniques combined with wavelet ...
... / PRNewswire/ -- Sigma-Aldrich® Corporation (Nasdaq: ... intended to more closely align its corporate structure ... President Research, will assume responsibility for the entire ... Essentials, Research Specialties and Research Biotech.  This newly ...
... 2011 Chimerix, Inc., a pharmaceutical company developing orally ... awarded a contract by the Biomedical Advanced Research and ... broad spectrum antiviral drug candidate, CMX001, as a medical ... CMX001 is a potential dual-use therapeutic with ...
Cached Biology Technology:Researchers get a grip on nervous system's receptors 2Researchers get a grip on nervous system's receptors 3Sigma-Aldrich Announces Organizational Changes 2Sigma-Aldrich Announces Organizational Changes 3Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 2Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 3Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 4
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
(Date:3/23/2015)... 23, 2015  In the 2014 fiscal year, irs.gov ... losses. This figure accounts for a fraction of the ... Nilson Report, exceeds $11 billion globally. The polygraph has ... crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test in ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... FLA research team led by Cary Pirone from the ... identified bilirubin in the popular Bird of Paradise plant. ... of the American Society for Horticultural Science,s journal ... this iconic tropical plant. Previously thought to ...
... from door-to-door interviews, Stanford University geographer Eric Lambin and ... rise to a broad range of land-use challenges ... Lyme disease in Belgium. For decades, orbiting satellites ... of the Earth, giving scientists an unprecedented view of ...
... development and successful initial tests on a substance that ... a fungus, brightening prospects for wider use of the ... that attack food crops. "Our finding is especially important ... control treatments like this will help to reduce dependence ...
Cached Biology News:First discovery of bilirubin in a flower announced 2Stanford land-use expert brings satellite data down to Earth 2Stanford land-use expert brings satellite data down to Earth 3Stanford land-use expert brings satellite data down to Earth 4
Request Info...
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
... supplied as 10X concentrated solutions. REact Buffer SetConsists ... the REact buffers and one 250 microl vial ... 1 ml vials of REact 1 Buffer four ... 1 ml vials of REact 3 Buffer and ...
Request Info...
Biology Products: